Crizotinib in ROS1-rearranged non-small-cell lung cancer. - Wikidata - wikimedia - TriplyDB

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

http://www.wikidata.org/entity/Q27853075

about

Crizotinib: from discovery to accelerated development to front-line treatment Targeted therapies and immunotherapy in non-small-cell lung cancer New targeted treatments for non-small-cell lung cancer - role of nivolumab The steady progress of targeted therapies, promising advances for lung cancer Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer Gene aberrations for precision medicine against lung adenocarcinoma Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis Novel targeted agents for the treatment of lung cancer in China The Evolution of Therapies in Non-Small Cell Lung Cancer Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance Using large-scale genomics data to identify driver mutations in lung cancer: methods and challenges Gastrointestinal cancers in the era of theranostics: Updates and future perspectives Predictive biomarkers in precision medicine and drug development against lung cancer Update in Lung Cancer 2014 Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.CIViC database Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report.Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.Technological considerations for genome-guided diagnosis and management of cancer The Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung Cancer Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date Testing for ROS1 in non-small cell lung cancer: a review with recommendations Second- and third-generation ALK inhibitors for non-small cell lung cancer China Experts Consensus on the Diagnosis and Treatment of Advanced Stage Primary Lung Cancer (2016 Version)Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice Organoid development in cancer genome discovery Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib Molecular markers: Implications for cytopathology and specimen collection

P2860

284401253e64da4d9f1ff1a803fafd15c6ad736b

P248

Q26738385-BB3AB7C8-1680-4BED-9D24-CA910A7402EF Q26738986-17E00A49-720E-41D9-85FC-D51C0F27248E Q26740988-5F8BD9B4-7681-4CCA-92E0-E642C9ACE7F9 Q26746895-4C2C5FB3-A0F4-49A7-8838-54C3358B4DDD Q26747276-2360847B-243F-44CA-B854-FDA0B96499DB Q26747329-C13B9518-AA13-4385-8275-B24A30DB55F0 Q26749348-A4798D28-6A6F-4249-A1A3-40A29E884FE9 Q26768158-28B18425-1CF3-4944-9507-E2AF1A36B5E0 Q26769659-A5BD3D2B-7143-4985-806C-FA625ADB8A6A Q26775347-DA2F6187-CCDB-4254-868C-E7092D0B36A4 Q26775388-77EC8DC9-F79D-4C91-AB58-BF638A588195 Q26778500-3CC6FC58-FC40-4D53-9BAE-B6ED1932A4C4 Q26784085-EA8901BB-BD36-414E-93B5-31B0EBF2C3B5 Q26786580-D4B978A4-D779-4182-BD89-7067E5BB91C4 Q26786932-ACE51C7F-3D3B-47FB-9FE3-29D99C2E8DC8 Q26799467-5FAAD1E2-4710-4E41-AF03-58868F605F7C Q26799900-6BFDEE56-AF5A-400B-B70B-9B5192E3E5EE Q26800833-407DCFD7-8596-441B-8201-9F5898A099E2 Q26801215-AD8D8CED-3B12-4273-A8F8-0DD4A071197C Q26824536-81802637-64B7-4B80-B52B-FF780227F67C Q27027385-8971DCB5-5FB8-4199-8EF8-D7BF6C535CEC Q27311389-A09026C6-6397-4880-928F-29A585F04B5D Q27612411-F166C2D1-1738-439E-A3F6-678554485003 Q27853157-8453390F-787F-4DCB-AD2B-A3D2E3AA5679 Q27853214-063763EC-988E-4F14-A513-3F77B185658E Q27853298-FE515BE2-EA4A-4CA3-BAD1-5240CA8D0B0B Q27853351-5A6F53E2-9CB2-4054-9B4A-701CC2BB075B Q27853360-DC23192C-8E67-42FE-924D-A09F5DB56D01 Q28066706-2264FA45-EA3E-435C-8793-DEFC7E92D689 Q28067196-39372C45-EC9E-4C62-874D-C3571B29ECC6 Q28067610-E4C4806D-36B4-4B08-904D-70987BEF1D1F Q28070062-052118C0-D3D0-4EFB-81DE-ACDC3E4D6735 Q28072496-4DCDF410-4BCA-4EDA-AEC7-F47676ED0133 Q28073920-70430E53-26D4-4235-9B23-C195E2FD2220 Q28075291-BD352E4B-7440-4F97-9159-96B6E434AD89 Q28075800-BD37233D-2282-4EF2-A5AF-96C35B582703 Q28083032-5F7F295E-9D1B-4F23-A310-55C60C5E1FF9 Q28083446-F8F5B0FF-91EE-4CD9-AA56-27C38C31E8A2 Q28083711-E913A7AB-9871-429C-BD6D-6B77FEA6E7FB Q28087155-D16DBE63-4582-4EAF-90CC-1C030486D4E7

P2860

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

http://www.wikidata.org/entity/Q27853075

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

@ast

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

@en

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

@nl

type

label

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

@ast

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

@en

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

@nl

altLabel

Crizotinib inROS1-Rearranged Non–Small-Cell Lung Cancer

@en

prefLabel

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

@ast

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

@en

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

@nl

P1433

Q27853075-207306C5-7D02-4DB9-BD31-9BA10DD646DC

P1476

Q27853075-CA0D9EF8-B4BA-47E9-A7FC-7C4C7C72DBAE

P2093

Q27853075-06B93A39-3F29-4529-82C2-965DB0A1BBC3

Q27853075-0AB07401-EA73-43F7-B2E8-7CAEE505AD9A

Q27853075-2D11CF14-E15C-48AD-BD27-8B115AE61882

Q27853075-32557916-2123-46AD-813E-DBC73AD5858C

Q27853075-63CA51E2-CD7F-402E-AE02-0002FB803ABB

Q27853075-70617D0F-FB0F-46FF-8CBC-3DC96C3426D7

Q27853075-7AFA183E-F301-44FE-A1CC-3844F5154294

Q27853075-91ABD520-638D-4058-9752-39AFE7C033D2

Q27853075-9C74C43A-215A-48D0-9CE8-1E293F641ED6

Q27853075-A27C99C7-0792-4C74-B786-453F4542138F

P2860

Q27853075-0290FBEB-2DFE-4B89-A40C-2A729E48F332

Q27853075-056F58B1-3E22-4E37-B6F0-722DCB4F5EA2

Q27853075-12176CF4-D0F7-4382-A9AB-700BB7239B3D

Q27853075-183B1D01-10E4-4798-B061-34339D27AD93

Q27853075-2E7B71D7-3F7A-47B3-925C-9C548AEBF881

Q27853075-2E819649-16E6-4D18-9282-32735927D5A2

Q27853075-37155F55-7246-4464-9672-1664450E2128

Q27853075-3ABE618F-572B-49A1-B6C4-6FB3C3EC1A71

Q27853075-3B00C5E7-8992-4ECB-A1E2-F4BAF09DD297

Q27853075-42A43667-22D7-4B5B-BABD-74F00EFE49AA

P304

Q27853075-055C0CD1-3816-4ED0-B261-54DCC84160E2

P31

Q27853075-705EAB41-F740-43F2-B2B3-FB9E51F9E0B0

P3181

Q27853075-6E3F017F-4F80-4F62-B290-9894FC32E0D5

P356

Q27853075-928A01FB-7BAB-4236-856F-E5F33418AFBB

P407

Q27853075-AC4681DE-9DEF-4E86-AD59-12B26575C50F

P433

Q27853075-DD008181-A9B9-4358-B324-365F25A52B8D

P478

Q27853075-990C129D-23E3-4C54-B431-5347E5BC5347

P50

Q27853075-828CAAC8-F894-4459-8252-21748C73787B

Q27853075-ED8D8C83-2199-4173-89B6-9424BB14DF61

P577

Q27853075-DEB4FFFD-5CFC-4099-8ED6-F76B41DC8F49

P698

Q27853075-B354D363-A26F-4A9F-874F-65C4DAA4E700

P921

Q27853075-117ED488-D3F0-4298-A73F-55623E437868

P932

Q27853075-98B77E6A-0AD9-4E90-87ED-CCADE18DB3F4

P3181

P356

P1433

The New England Journal of Medicine

P1476

Crizotinib in ROS1-rearranged non-small-cell lung cancer

@en

P2093

A John Iafrate

http://www.w3.org/2001/XMLSchema#string

Alice T Shaw

http://www.w3.org/2001/XMLSchema#string

Benjamin J Solomon

http://www.w3.org/2001/XMLSchema#string

D Ross Camidge

http://www.w3.org/2001/XMLSchema#string

Geoffrey I Shapiro

http://www.w3.org/2001/XMLSchema#string

Gregory J Riely

http://www.w3.org/2001/XMLSchema#string

James G Christensen

http://www.w3.org/2001/XMLSchema#string

Jeffrey W Clark

http://www.w3.org/2001/XMLSchema#string

Keith D Wilner

http://www.w3.org/2001/XMLSchema#string

Lesley M Tye

http://www.w3.org/2001/XMLSchema#string

P2860

EPLIN, epithelial protein lost in neoplasm

Characterization of an activated human ros gene

Moesin: a member of the protein 4.1-talin-ezrin family of proteins

Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus encodes for a transmembrane receptorlike molecule

Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1

Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy

Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

ROS1 rearrangements define a unique molecular class of lung cancers.

P304

1963-1971

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

560062

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1406766

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

371

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25264305

http://www.w3.org/2001/XMLSchema#string

P921

P932

4264527

http://www.w3.org/2001/XMLSchema#string